Histone deacetylase inhibitor resminostat in combination with sorafenib counteracts platelet-mediated pro-tumoral effects in hepatocellular carcinoma

由 Streubel, Gundula, Schrepfer, Sabine, Kallus, Hannah, Parnitzke, Ulrike, Wulff, Tanja, Hermann, Frank, Borgmann, Matthias, Hamm, Svetlana
發表在 Sci Rep (2021)